AstraZeneca wins approval for new diabetes drug
The FTSE 100 pharmaceuticals firm, AstraZeneca, has won Europe-wide approval for its diabetes drug Komboglyze.
The FTSE 100 pharmaceuticals firm, AstraZeneca, has won Europe-wide approval for its diabetes drug Komboglyze.
The treatment, which was developed in conjunction with US peer Bristol-Myers Squibb, helps glycaemic control in adult patients with type 2 diabetes.
The approval comes following a study involving 4,326 patients.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Type 2 diabetes accounts for approximately 90 to 95% of all cases of diagnosed diabetes in adults. In Europe alone there are around 50 million people suffering with the condition.
The share price fell marginally by 0.04% to 2,820p by 08:20.
BS
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Sir David McMurtry: Renishaw founder and Concorde engineer
Sir David McMurtry, co-founder of Renishaw, made a unique contribution to Britain. We look back at his legacy
By Jamie Ward Published
-
How to transfer an ISA
We explain everything you need to know about transferring an ISA
By Rebekah Evans Published